Pair Name	Licochalcone B, TNF-related apoptosis inducing ligand
Disease Info	[ICD-11: 2C12]	Hepatocellular carcinoma		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Down-regulation	Phosphorylation	AKT1	hsa207
	Up-regulation	Phosphorylation	ATM	hsa472
	Up-regulation	Cleavage	CASP8	hsa841
	Down-regulation	Expression	CCNB1	hsa891
	Down-regulation	Expression	CCND1	hsa595
	Down-regulation	Phosphorylation	CDK1	hsa983
	Down-regulation	Expression	CDK1	hsa983
	Up-regulation	Phosphorylation	CHEK2	hsa11200
	Up-regulation	Expression	DDIT3	hsa1649
	Down-regulation	Expression	EIF2AK3	hsa9451
	Up-regulation	Expression	H2AX	hsa3014
	Up-regulation	Expression	HSPA5	hsa3309
	Up-regulation	Phosphorylation	MAPK1	hsa5594
	Up-regulation	Phosphorylation	MAPK14	hsa1432
	Up-regulation	Phosphorylation	MAPK3	hsa5595
	Up-regulation	Phosphorylation	MAPK8	hsa5599
	Up-regulation	Phosphorylation	MAPK9	hsa5601
	Up-regulation	Cleavage	PARP1	hsa142
	Up-regulation	Cleavage	PARP1	hsa142
	Up-regulation	Expression	PSMD9	hsa5715
	Down-regulation	Phosphorylation	RPS6KB1	hsa6198
	Up-regulation	Expression	TNFRSF10A	hsa8797
	Up-regulation	Expression	TNFRSF10B	hsa8795
Result	LCB exhibits cytotoxic activity through modulation of the Akt/mTOR, ER stress and MAPK pathways in HCC cells and effectively enhances TRAIL sensitivity through the upregulation of DR5 expression in ERK- and JNK-dependent manner. Combination therapy with LCB and TRAIL may be an alternative treatment strategy for HCC.